|Day's Range||31.50 - 31.58|
|52 Week Range||25.33 - 31.73|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.08%|
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.
On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.
Investors seeking low fees on developed markets exposure should look at this ETF.